Conmana (icotinib)

P=N/A, N=88, Not yet recruiting, Beijing Hospital; Beijing Hospital

P=N/A, N=200, Not yet recruiting, Beijing Chest Hospital Capital Medical University; Beijing Chest Hospital Capital Medical University

P4, N=178, Not yet recruiting, Beijing chest hospital capital medical university; Beijing Chest Hospital Capital Medical University

A female patient in her late 40s with Stage IVB EGFR L858R lung adenocarcinoma exhibiting high BCL-2 expression was treated with radiotherapy and icotinib...Upon AML relapse, a fast in vivo MiniPDX drug sensitivity assay guided the selection of a salvage combination therapy (Selinexor, Decitabine, and Venetoclax)...This case highlights the complexity of managing these distinct malignancies, where the lung tumor's BCL-2 expression provided a rationale for the AML therapy. Furthermore, the MiniPDX assay proved valuable in guiding personalized therapy for refractory disease, demonstrating the potential of functional precision medicine strategies.

Metastatic burden remains a key prognostic factor. These findings support dose escalation as a viable strategy for frail populations with limited access to next-generation TKIs.

Two patients experienced disease recurrence and were successfully switched to osimertinib upon identification of an EGFR (T790M) mutation. This study suggests a potential DFS benefit and well-tolerated profile of adjuvant icotinib in patients with EGFR-mutated high-risk stage IB NSCLC. However, longer-term follow-up is necessary to assess the long-term outcomes.

This NMA revealed that cases with EGFR-mutated NSCLC may benefit from different first-line treatment regimens according to their clinicopathological characteristics. On the whole, osimertinib plus CT and amivantamab plus lazertinib emerged as the most noticeable treatment modalities for such cases. (PROSPERO ID: CRD42024506995).

Patients received first-generation EGFR-TKIs treatment, including gefitinib, erlotinib and icotinib, then received Gamma Knife consolidation therapy for the treatment of residual lesions in the chest, with a total of 10-17 sessions administered five times a week. In conclusion, combining first-generation EGFR-TKIs with Gamma Knife therapy can delay EGFR resistance, extend PFS and OS, and result in a low incidence of toxic and side effects. However, further prospective randomized controlled studies are required to validate the results of the present study.

P4, N=37, Not yet recruiting, Tianjin Cancer Hospital Airport Hospita; Tianjin Cancer Hospital Airport Hospita

Rates of adverse events of grade 3 or higher were 8.3%, 6.0% and 2.4% for the 12-month icotinib, 6-month icotinib, and observation groups, respectively. Adjuvant icotinib for 12 months or 6 months following adjuvant chemotherapy improved DFS and OS compared with observation in patients with resected EGFR-mutated stage II-IIIA NSCLC with a manageable safety profile, supporting it as a potential treatment option.

P2, N=128, Not yet recruiting, Jining Medical University Affiliated Hospital; Jining Medical University Affiliated Hospital | N=30 --> 128

These findings conclusively demonstrated that pharmacological inhibition of CSF-1R activity by ABSK021 resulted in significant anti-tumor effects in preclinical osteosarcoma models with CSF-1R overexpression. The high prevalence of CSF-1R expression observed in osteosarcoma patient samples highlights the potential clinical use of ABSK021, either as a monotherapy or in combination with chemotherapy, as a promising therapeutic strategy for osteosarcoma patients with CSF-1R as a potential predictive biomarker.